Business Description
China National Accord Medicines Corp Ltd
NAICS : 325411
ISIN : CNE0000009M8
Compare
Compare
Traded in other countries / regions
000028.China IPO Date
1993-08-09Description
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.05 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | 2.06 | |||||
| Interest Coverage | 10.27 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 2.86 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.6 | |||||
| 3-Year EBITDA Growth Rate | 9.7 | |||||
| 3-Year EPS without NRI Growth Rate | 5.4 | |||||
| 3-Year FCF Growth Rate | 8.3 | |||||
| 3-Year Book Growth Rate | 7.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.75 | |||||
| 9-Day RSI | 13.64 | |||||
| 14-Day RSI | 20.92 | |||||
| 6-1 Month Momentum % | 15.51 | |||||
| 12-1 Month Momentum % | 30.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 45.16 | |||||
| Days Sales Outstanding | 87.88 | |||||
| Days Payable | 96.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.59 | |||||
| Dividend Payout Ratio | 0.17 | |||||
| 3-Year Dividend Growth Rate | 14.5 | |||||
| Forward Dividend Yield % | 4.47 | |||||
| 5-Year Yield-on-Cost % | 8.9 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 12.19 | |||||
| Operating Margin % | 3.41 | |||||
| Net Margin % | 2.13 | |||||
| ROE % | 10.12 | |||||
| ROA % | 3.49 | |||||
| ROIC % | 9.95 | |||||
| ROC (Joel Greenblatt) % | 29.03 | |||||
| ROCE % | 12.97 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.69 | |||||
| PE Ratio without NRI | 15.71 | |||||
| Shiller PE Ratio | 19.99 | |||||
| Price-to-Owner-Earnings | 18.65 | |||||
| PEG Ratio | 0.84 | |||||
| PS Ratio | 0.33 | |||||
| PB Ratio | 1.52 | |||||
| Price-to-Tangible-Book | 1.92 | |||||
| Price-to-Free-Cash-Flow | 9.39 | |||||
| Price-to-Operating-Cash-Flow | 8.39 | |||||
| EV-to-EBIT | 8.22 | |||||
| EV-to-EBITDA | 8.22 | |||||
| EV-to-Revenue | 0.3 | |||||
| EV-to-FCF | 8.49 | |||||
| Price-to-Projected-FCF | 0.74 | |||||
| Price-to-DCF (Earnings Based) | 0.32 | |||||
| Price-to-DCF (FCF Based) | 0.23 | |||||
| Price-to-Median-PS-Value | 0.68 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.11 | |||||
| Price-to-Graham-Number | 1.16 | |||||
| Price-to-Net-Current-Asset-Value | 4.54 | |||||
| Earnings Yield (Greenblatt) % | 12.17 | |||||
| Forward Rate of Return (Yacktman) % | 13.31 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
China National Accord Medicines Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 85,227.545 | ||
| EPS (TTM) (HK$) | 3.262 | ||
| Beta | 0.6 | ||
| Volatility % | 27.92 | ||
| 14-Day RSI | 20.92 | ||
| 14-Day ATR (HK$) | 0.815381 | ||
| 20-Day SMA (HK$) | 20.257308 | ||
| 12-1 Month Momentum % | 30.76 | ||
| 52-Week Range (HK$) | 15.346153 - 21.85 | ||
| Shares Outstanding (Mil) | 428.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China National Accord Medicines Corp Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
China National Accord Medicines Corp Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
China National Accord Medicines Corp Ltd Frequently Asked Questions
What is China National Accord Medicines Corp Ltd(SZSE:200028)'s stock price today?
The current price of SZSE:200028 is HK$20.21. The 52 week high of SZSE:200028 is HK$21.85 and 52 week low is HK$15.35.
When is next earnings date of China National Accord Medicines Corp Ltd(SZSE:200028)?
The next earnings date of China National Accord Medicines Corp Ltd(SZSE:200028) is .
Does China National Accord Medicines Corp Ltd(SZSE:200028) pay dividends? If so, how much?
The Dividend Yield %  of China National Accord Medicines Corp Ltd(SZSE:200028) is 3.59% (As of Today), Highest Dividend Payout Ratio of China National Accord Medicines Corp Ltd(SZSE:200028) was 0.26. The lowest was 0.09. And the median was 0.12. The  Forward Dividend Yield % of China National Accord Medicines Corp Ltd(SZSE:200028) is 4.47%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
